Journal
JOURNAL OF IMMUNOLOGY
Volume 186, Issue 1, Pages 53-61Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1002358
Keywords
-
Categories
Funding
- Merck Co., Inc.
- National Institutes of Health [AI082292, AI071302]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071302, R01AI082292] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Dendritic cells (DCs) respond to chemotactic signals to migrate from sites of infection to secondary lymphoid organs where they initiate the adaptive immune response. The key chemokines directing their migration are CCL19, CCL21, and CXCL12, but how signals from these chemokines are integrated by migrating cells is poorly understood. Using a microfluidic device, we presented single and competing chemokine gradients to murine bone-marrow derived DCs in a controlled, time-invariant microenvironment. Experiments performed with counter-gradients revealed that CCL19 is 10-100-fold more potent than CCL21 or CXCL12. Interestingly, when the chemoattractive potencies of opposing gradients are matched, cells home to a central region in which the signals from multiple chemokines are balanced; in this region, cells are motile but display no net displacement. Actin and myosin inhibitors affected the speed of crawling but not directed motion, whereas pertussis toxin inhibited directed motion but not speed. These results provide fundamental insight into the processes that DCs use to migrate toward and position themselves within secondary lymphoid organs. The Journal of Immunology, 2011, 186: 53-61.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available